Liver injury linked to hep C treatments

29 August 2019
fda-big

A trio of hepatitis C regimens has been linked to cases of worsening function or failure of the liver.

Those affected are some of those with advanced liver disease taking AbbVie’s (NYSE: ABBV) Mavyret (glecaprevir/pibrentasvir), Merck & Co’s (NYSE: MRK) Zepatier (elbasvir/grazoprevir) or Gilead Sciences’ (Nasdaq: GILD) Vosevi (sofosbuvir/velpatasvir/voxilaprevir).

The US Food and Drug Administration (FDA) has put out a MedWatch safety alert warning of these rare occurrences. The agency identified 63 cases of worsening liver function, or decompensation, among hepatitis C patients taking these regimens.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology